Skip to content

Acute Effects of Menthol Gargle and Buccal Film on Anaerobic Capacity and Respiratory Parameters in Male Volleyball Players

Acute Effects of Menthol Gargle and Buccal Film on Anaerobic Capacity and Respiratory Parameters in Male Volleyball Players

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07745049
Enrollment
16
Registered
2026-08-04
Start date
2025-11-25
Completion date
2026-01-05
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menthol

Keywords

Menthol, anaerobic performance, respiratory parameters.

Brief summary

Menthol activates the transient receptor potential melastatin 8 (TRPM8) channel and can alter thermal and respiratory perception without producing an actual reduction in body or tissue temperature. Evidence on whether oral menthol improves short-duration maximal (anaerobic) performance is limited and inconsistent, and almost all existing exercise studies have delivered menthol as a mouth rinse, solution, gel or topical preparation. A menthol-containing buccal film represents a distinct route of oral administration, because it adheres to the buccal mucosa and may alter the residence time and release profile of menthol in the oral cavity. No controlled exercise study has compared a menthol-containing buccal film with menthol mouth-rinsing and a placebo condition in athletes. This single-blind, randomized, three-condition crossover trial compares the acute effects of a placebo (water control), menthol mouth-rinsing, and a menthol-containing buccal film on anaerobic performance in male volleyball players. The primary outcome is anaerobic performance measured with the 30-second Wingate Anaerobic Power Test. Secondary (exploratory) outcomes are respiratory function assessed by spirometry, post-exercise blood lactate concentration, and post-exercise plasma hypoxia-inducible factor-1 alpha (HIF-1alpha) concentration. Each participant completes all three conditions in a randomized order, separated by 72-hour washout periods. Both active conditions deliver a standardized total of 10 mg of L-menthol. All testing sessions are conducted at the same time of day, under similar environmental conditions, and by the same researcher.

Detailed description

BACKGROUND AND RATIONALE Volleyball is an intermittent team sport characterized by repeated jumps, sudden accelerations, short-duration maximal or near-maximal movements, and limited recovery intervals. Rapid lower-extremity power production and the ability to sustain it across repeated high-intensity actions are therefore central to volleyball performance. Menthol is a natural monoterpene that produces a cooling sensation by activating the TRPM8 channel in thermosensory neurons. This sensory response does not correspond to an actual reduction in skin or core temperature, which suggests that any acute effect of oral menthol on exercise may operate through perceptual and behavioral rather than thermal mechanisms. Findings on strength, power and high-intensity exercise are more limited and inconsistent than those on thermal perception, and recent meta-analytic evidence does not support menthol mouth-rinsing as a consistent ergogenic strategy. Whether menthol affects anaerobic performance under thermoneutral conditions during short-duration maximal exercise remains unclear. In most exercise studies menthol has been delivered as a mouth rinse, beverage, gel or topical preparation. A buccal film is a distinct oral dosage form: it adheres to the buccal mucosa and, depending on formulation, can alter the residence time and release profile of the incorporated compound in the oral cavity. In pharmaceutical research menthol has generally been studied as a permeation enhancer or excipient rather than as the primary active compound. The dissolution rate, release profile, mucosal absorption and sensory exposure produced by a menthol-containing buccal film cannot be inferred from mouth-rinsing studies. The buccal film is therefore investigated here as an experimental route of administration with no established physiological or ergogenic superiority, not as a presumed enhancement. HIF-1alpha regulates genes associated with glycolytic metabolism, oxygen homeostasis and angiogenesis, and exercise has been shown to affect HIF-1alpha protein levels and HIF-1-related signaling in human skeletal muscle. At the cell-culture level, menthol-induced TRPM8 activation has been reported to stabilize HIF-1alpha protein through a calcium- dependent, oxygen-independent mechanism. HIF-1alpha is therefore included as an exploratory biomarker of the biological response to high-intensity exercise under the three conditions. OBJECTIVES Primary objective: to compare the acute effects of placebo (water control), menthol mouth-rinsing, and a menthol-containing buccal film on anaerobic performance assessed by the Wingate Anaerobic Power Test in male volleyball players. Secondary (exploratory) objectives: to compare the effects of the three conditions on respiratory function, post-exercise blood lactate concentration, and post-exercise plasma HIF-1alpha concentration. HYPOTHESIS There will be significant differences among the placebo, menthol mouth-rinsing, and menthol-containing buccal-film conditions in anaerobic performance, respiratory function, blood lactate concentration, and plasma HIF-1alpha concentration. DESIGN Single-blind, randomized, three-condition crossover trial. Each participant completes all three conditions. The order of conditions is determined by randomization. A 72-hour washout period separates conditions to minimize carryover effects. SAMPLE SIZE An a priori power analysis was conducted using G\*Power 3.1.9.7 for a repeated-measures within-subjects ANOVA with one group and three repeated measurements, assuming an effect size f = 0.35, alpha = 0.05, power (1-beta) = 0.80, correlation among repeated measures r = 0.50, and nonsphericity correction epsilon = 1.00. The required minimum sample size was 15 participants (achieved power 0.81). Nineteen volunteers were assessed for eligibility to allow for attrition. INTERVENTIONS Placebo (water control): a total of 40 mL of tap water given as two separate 20 mL volumes; each volume is rinsed around the mouth for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). Menthol gargle (MG): a total of 40 mL of solution containing 10 mg L-menthol (0.025% w/v), given as two separate 20 mL volumes; each volume is rinsed for 30 seconds and expectorated without swallowing (total rinsing time 60 seconds). The concentration was selected based on the range of L-menthol concentrations used in exercise studies. Menthol buccal film (MBF): a film containing a total of 10 mg L-menthol placed on the buccal mucosa within the oral cavity. Total L-menthol content is standardized at 10 mg across both active conditions. PROCEDURES PER SESSION 1. Body weight is remeasured to set the Wingate resistance load. 2. Standardized 15-minute warm-up (10 minutes light running, 5 minutes stretching). 3. Administration of the assigned condition (P, MG or MBF). 4. Spirometry in the seated position, with nose clip and disposable mouthpiece, performed according to the 2019 ATS/ERS spirometry standardization statement. At least three acceptable maneuvers are obtained and FEV1/FVC repeatability is verified. The highest FVC and FEV1 from acceptable maneuvers are used. 5. Approximately one minute after spirometry, the 30-second Wingate Anaerobic Power Test is performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight, with standardized verbal encouragement, participants remaining seated. 6. Immediately after the Wingate test, a 5 mL venous blood sample is drawn from the antecubital vein into an EDTA tube. BLOOD SAMPLE HANDLING Tubes are inverted 8-10 times. Within 30 minutes of collection, samples are centrifuged at 1500 x g for 15 minutes at 4 degrees C. Plasma is aliquoted into sterile microtubes without contacting the cellular layer and stored at -80 degrees C until analysis. BIOCHEMICAL ANALYSES Plasma HIF-1alpha is measured by a commercial human HIF-1alpha sandwich ELISA (Reed Biotech Ltd., Wuhan, China; catalogue no. RE2787H) and expressed as pg/mL. Lactate is measured by a commercial lactic acid assay kit (Reed Biotech Ltd., Wuhan, China; catalogue no. RE10064) and expressed as mmol/L. Samples and standards are analyzed in duplicate; absorbance is read on a BioTek ELx800 microplate reader. STANDARDIZATION AND CONTROL OF CONFOUNDERS Participants refrain from menthol-containing products for one week before the first condition, and from caffeine, alcohol, menthol-containing products and strenuous exercise for 72 hours before each condition. Dietary intake is recorded for the 72 hours before the first condition and participants are asked to maintain a similar dietary pattern before subsequent conditions. All sessions are conducted at 72-hour intervals, at the same time of day, under similar environmental conditions, and by the same researcher. Ergometer seat and handlebar settings are individualized at the first session and kept unchanged thereafter. BLINDING Participants are not informed of the study hypothesis or the expected direction of effects. The researcher preparing and administering the conditions is aware of the allocation. Because of the differences between routes of administration and the perceptible cooling sensation produced by menthol, complete participant blinding is not achievable; blinding is therefore implemented by restricting participants' access to information about the hypothesis and expected effects. STATISTICAL ANALYSIS Continuous variables are summarized as mean and standard deviation. Normality is assessed with the Shapiro-Wilk test. Differences among conditions are examined with one-way repeated-measures ANOVA with condition as a three-level within-subject factor. Sphericity is assessed with Mauchly's test. For variables with a significant omnibus condition effect, pairwise comparisons are performed with Bonferroni correction. Effect size is reported as partial eta squared. All tests are two-tailed with alpha set at 0.05.

Interventions

OTHERPlacebo (water control)

40 mL of tap water administered as two 20 mL volumes; each rinsed for 30 seconds and expectorated without swallowing.

OTHERMenthol gargle

40 mL of aqueous solution containing 10 mg L-menthol (0.025% w/v), administered as two 20 mL volumes; each rinsed for 30 seconds and expectorated without swallowing.

OTHERMenthol buccal film

Buccal film containing 10 mg L-menthol, applied to the buccal mucosa.

Sponsors

Vedat Cinar
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)

Masking description

Participants were not informed of the study hypothesis or the expected direction of effects. The researcher administering the conditions was aware of allocation. Complete participant blinding was not achievable because of differences between routes of administration and the perceptible cooling sensation of menthol.

Intervention model description

Each participant completed all three conditions (placebo, menthol gargle, menthol buccal film) in a randomized order, with a 72-hour washout period between conditions.

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Healthy male volleyball player * Training regularly * No chronic disease * No active injury * Non-smoker * No alcohol consumption * No regular use of medications, dietary supplements or performance-enhancing substances * No known hypersensitivity to menthol * Provision of written informed consent * Allergy to menthol or to any other component used in the interventions * Pharmacological treatment within the preceding three months * History of chronic disease or serious injury * Any health condition that could affect test performance

Design outcomes

Primary

MeasureTime frameDescription
Peak power during the Wingate Anaerobic Power TestDuring the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.Peak power output (W) during a 30-second Wingate Anaerobic Power Test performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight. Calculated with Monark Anaerobic Test Software Version 3.
Mean power during the Wingate Anaerobic Power TestDuring the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.Mean power output (W) across the 30-second Wingate Anaerobic Power Test performed on a mechanically braked Monark 834E cycle ergometer at a resistance of 7.5% of body weight. Calculated with Monark Anaerobic Test Software Version 3.
Relative peak power during the Wingate Anaerobic Power TestDuring the 30-second Wingate Anaerobic Power Test performed after each intervention, at each of the three study visits separated by 72 hours.Peak power output normalized to body weight (W/kg) during a 30-second Wingate Anaerobic Power Test. Body weight was remeasured on each testing day.
Post-exercise blood lactate concentrationImmediately after completion of the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.Lactate concentration (mmol/L) in plasma obtained from a 5 mL venous blood sample drawn from the antecubital vein into an EDTA tube immediately after the Wingate test, centrifuged at 1500 x g for 15 minutes at 4 degrees C within 30 minutes of collection, and measured with a commercial lactic acid assay kit (Reed Biotech Ltd., catalogue no. RE10064) in duplicate.

Secondary

MeasureTime frameDescription
Forced vital capacity (FVC)After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.Forced vital capacity (L) measured by spirometry in the seated position with a nose clip and disposable mouthpiece, according to the 2019 ATS/ERS spirometry standardization statement. At least three acceptable maneuvers were obtained; the highest acceptable value was used.
Forced expiratory volume in 1 second (FEV1)After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.FEV1 (L) measured by spirometry according to the 2019 ATS/ERS standardization statement. At least three acceptable maneuvers were obtained and FEV1 repeatability was verified; the highest acceptable value was used.
Peak expiratory flow (PEF)After each intervention and immediately before the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.Peak expiratory flow (L/s) measured by spirometry according to the 2019 ATS/ERS standardization statement.
Post-exercise plasma HIF-1alpha concentrationImmediately after completion of the Wingate Anaerobic Power Test, at each of the three study visits separated by 72 hours.Plasma hypoxia-inducible factor-1 alpha concentration (pg/mL) measured by a commercial human HIF-1alpha sandwich ELISA (Reed Biotech Ltd., catalogue no. RE2787H) in duplicate, from a 5 mL venous EDTA blood sample drawn immediately after the Wingate test and processed within 30 minutes. Exploratory outcome.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026